Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

[Case of pemetrexed-induced acute lung injury].

Sakamoto S, Kaburaki K, Sakaguchi S, Sano G, Sugino K, Isobe K, Shibuya K, Kurosaki A, Uekusa T, Homma S.

Nihon Kokyuki Gakkai Zasshi. 2009 May;47(5):415-20. Japanese.

PMID:
19514505
2.

Fatal pemetrexed-induced lung injury in patients with advanced mesothelioma: a report of two cases.

Nagata K, Kaji R, Tomii K.

J Thorac Oncol. 2010 Oct;5(10):1714-5. doi: 10.1097/JTO.0b013e3181f1378e. No abstract available.

3.

A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.

Kao SC, McCaughan B, Muljono A, Boyer M.

J Thorac Oncol. 2010 Mar;5(3):405-6. doi: 10.1097/JTO.0b013e3181c8cb16. No abstract available.

4.

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.

J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.

5.

Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?

Li L, Razak AR, Hughes A.

Lung Cancer. 2009 May;64(2):207-10. doi: 10.1016/j.lungcan.2008.08.016.

PMID:
18926592
6.

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.

Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368.

7.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

8.

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M.

Ann Oncol. 2008 Feb;19(2):370-3.

9.

An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.

Zilembo N, Vitali M, Pietrantonio F, Platania M, Del Vecchio M, Bajetta E.

Tumori. 2010 Nov-Dec;96(6):1031-4. Review.

10.

Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.

Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S.

Lung Cancer. 2012 Mar;75(3):353-9. doi: 10.1016/j.lungcan.2011.08.002.

PMID:
21890228
11.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
12.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.

PMID:
18349397
13.

[A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].

Shukuya T, Takahashi T, Nakamura Y, Yamamoto N.

Gan To Kagaku Ryoho. 2010 Mar;37(3):487-90. Japanese.

PMID:
20332689
14.

Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Berardi R, Caramanti M, Fiordoliva I, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Castagnani M, Rovinelli F, Onofri A, Cascinu S.

Support Care Cancer. 2015 Mar;23(3):621-6. doi: 10.1007/s00520-014-2398-6.

PMID:
25142706
15.

Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.

Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.

Clin Cancer Res. 2009 Jan 1;15(1):382-9. doi: 10.1158/1078-0432.CCR-08-0128.

16.

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H.

J Clin Oncol. 2002 Aug 15;20(16):3533-44.

PMID:
12177114
17.

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.

J Clin Oncol. 2006 Mar 20;24(9):1443-8.

PMID:
16549838
18.

Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.

Agatsuma T, Koizumi T, Yasuo M, Urushihata K, Tsushima K, Yamamoto H, Hanaoka M, Fukushima M, Honda T, Kubo K.

Jpn J Clin Oncol. 2010 Dec;40(12):1180-3. doi: 10.1093/jjco/hyq101.

19.

Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Adusumilli PS.

Cancer. 2014 Nov 1;120(21):3268-71. doi: 10.1002/cncr.28883. No abstract available.

20.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.

Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.

Respir Investig. 2014 Mar;52(2):101-6. doi: 10.1016/j.resinv.2013.07.002.

PMID:
24636265
Items per page

Supplemental Content

Support Center